Acadia Pharmaceuticals (ACAD +10.6%) jumps after announcing an $86.4M private placement. The...

|By:, SA News Editor

Acadia Pharmaceuticals (ACAD +10.6%) jumps after announcing an $86.4M private placement. The securities are to be sold at $4.43 per share, and will be used primarily to support completion of it's Phase III pimavanserin program, including a planned confirmatory Phase III pivotal trial in Parkinson's disease psychosis.